INDICATIONS ZORYVE cream, 0.05%, is indicated for topical treatment of mild to moderate atopic dermatitis in pediatric patients 2 to 5 years of age. ZORYVE cream, 0.15%, is indicated for topical ...

A recent study published in JAMA Dermatology has demonstrated that PROMIS measures are valid tools for evaluating the physical, emotional, and social effects of chronic skin diseases.

InnoCare Pharma Ltd recently said that, driven by robust sales of its flagship anti-cancer drug and income from overseas licensing agreements, it expects to more than double its revenue in 2025 and ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q4 2025 Earnings Call Transcript January 30, 2026 Regeneron Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $11.44, expectations were ...

Topical pumecitinib 3% gel shows strong efficacy and good tolerability in mild-to-moderate atopic dermatitis. Explore the ...

Most patients expressed an interest in understanding how environmental-climate factors affect their atopic dermatitis.

Amlitelimab is effective at improving moderate to severe AD across all body regions, including the difficult-to-treat head and neck region.

A new study published in the Journal of the European Academy of Dermatology and Venerology showed that nemolizumab, an ...

Oncodermatology is evolving with nonsurgical approaches and immune checkpoint inhibitors, improving outcomes in aggressive ...

Johnson & Johnson has discontinued a phase 2 trial of one of its pipeline candidates for atopic dermatitis (AD), after it failed to meet efficacy expectations. In a statement, J&J said that ...

No longer confined to cancer centers, skin complications of cancer therapies are now commonly encountered at the community level and require the care of a dermatologist.

Turn Therapeutics Inc., operates as a pharmaceuticals company that develops drugs to treat diseases of the skin, nails, and eye. The company's delivery technology penetrates the skin and nails and ...